Research
Cellular
Resmetirom achieved resolution of steatohepatitis without worsening of fibrosis in 26%-30% of participants compared to 10% for placebo.
Resmetirom may be an effective treatment option for patients with MASH and moderate to advanced liver fibrosis.
StrongSupportsmedium confidence
In the MAESTRO-NASH trial, treatment with resmetirom achieved the 2 primary endpoints of resolution of steatohepatitis without worsening of fibrosis (26%-30% compared with 10% for resmetirom and placebo, respectively).
Why this rating
Based on findings from a large clinical trial (MAESTRO-NASH).
Source
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Vincent Chen et al. · Hepatology · 2024
DOI 10.1097/hep.0000000000001112
otherCited 145×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →